Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC).
Kenneth H. Kim
No relevant relationships to disclose
Danijela Jelovac
No relevant relationships to disclose
Deborah Kay Armstrong
Consultant or Advisory Role - Genentech; Morphotek
Research Funding - Eisai (I); Exelixis (I)
Susan Weil
Employment or Leadership Position - Morphotek
Martin Phillips
Employment or Leadership Position - Morphotek
Benjamin M Schwartz
No relevant relationships to disclose
Jacob Michael Estes
No relevant relationships to disclose
Ronald David Alvarez
Consultant or Advisory Role - Morphotek
Research Funding - Morphotek